A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Golimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GO-VIBRANT
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 16 Jun 2018 Results assessing improvements in Psoriasis and DLQI with Golimumab treatment (n=394) presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results of a safety integrated analysis of Golimumab treatment from phase 3 studies (GO-FURTHER, GO-VIBRANT and GO-ALIVE; n=1279) presented at the 19th Annual Congress of the European League Against Rheumatism
    • 08 Nov 2017 24-Week results assessing effects of Golimumab on mental and physical health, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top